SCHEMBL694976

SCHEMBL694976

Fc1ccc(-c2cc3c[c]c(Cl)cc3[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
CTSV O60911 1/20 0.43
CTSL P07711 1/20 0.43
CYP1A1 P04798 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694967 0.85 CTSV (0.44) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL694886 0.82 CYP1A1 (0.44) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL695284 0.78 ALDH1A1 (0.57) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL29804879 0.75 MEN1 (0.70) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL695386 0.75 CYP1A1 (0.45) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL6585157 0.75 MEN1 (0.70) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL16720322 0.73 CTSV (0.43) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL30869753 0.73 CYP1A1 (0.68) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL695264 0.72 CTSV (0.49) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL2061664 0.72 RAB9A (0.71) KDM4EMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197450-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2017-08-02 EP disclosed
WO-2016046130-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-03-31 WO disclosed
EP-2421825-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP disclosed
WO-2010124108-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed